Modulation of hemostatic mechanisms in bacterial infectious diseases

Blood

Volumn 96, Issue 7, 2000, Pages 2329-2337

  Tapper, Hans ^a   Herwald, Heiko ^a  

^a LUND UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBIN III; COMPLEMENT COMPONENT C1S INHIBITOR; COMPLEMENT COMPONENT C4B; PROTEIN C; PROTEIN S; THROMBOMODULIN; TISSUE FACTOR PATHWAY INHIBITOR;

ANTIBIOTIC RESISTANCE; BACTERIAL INFECTION; BLEEDING DISORDER; BLOOD CLOTTING; BLOOD VESSEL INJURY; FIBRINOLYSIS; HEMOSTASIS; IMMUNE RESPONSE; PRIORITY JOURNAL; REVIEW; SEPSIS; SEPTIC SHOCK; TISSUE INJURY;

EID: 0034307654     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v96.7.2329.h8002329_2329_2337     Document Type: Review

References (188)

1. The challenges of emerging infectious diseases: Development and spread of multiply-resistant bacterial pathogens
2. Antibiotic resistance: What can we do?
3. Antithrombin replacement in patients with sepsis and septic shock
4. Linkage between inflammation and coagulation: An update on the molecular basis of the crosstalk
5. Review: Infectious diseases and coagulation disorders
6. Cell biology of tissue factor, the principal initiator of blood coagulation
7. The molecular basis of blood coagulation
8. Contact system: A vascular biology modulator with anticoagulant, profibrinolytic, antiadhesive, and proinflammatory attributes
9. Bioregulation of kinins: Kallikreins, kininogens, and kininases
10. Activation of human blood coagulation factor XI independent of factor XII: Factor XI is activated by thrombin and factor XIa in the presence of negatively charged surfaces
11. Tissue factor and the extrinsic pathway of coagulation during infection and vascular inflammation
12. Platelets and factor XI bypass the contact system of blood coagulation
13. Thrombin, thrombomodulin and TAFI in the molecular link between coagulation and fibrinolysis
14. Fibrinolysis and the contact system: A role for factor XI in the down-regulation of fibrinolysis
15. Structure-function relationships of the thrombin-thrombomodulin interaction
16. Role of antithrombin III as a regulator of in vivo coagulation
17. Structure and function of C1 inhibitor
18. Tissue factor pathway inhibitor and the revised theory of coagulation
19. Thrombin-mediated activation of factor XI results in a thrombin-activatable fibrinolysis inhibitor-dependent inhibition of fibrinolysis
20. The plasminogen activator/plasmin system
21. The effects of plasmin and protein Ca on factor VIII:C and VIII:CAg
22. Inactivation of factor Va by plasmin
23. The plasminogen (fibrinolytic) system
24. Mechanism of action of plasminogen activators
25. Biochemical and biological aspects of the plasminogen activation system
26. Regulation of plasmin, miniplasmin, and streptokinase-plasmin complex by alpha 2-antiplasmin, alpha 2-macroglobulin, and antithrombin III in the presence of heparin
27. Fibrinolytic system of vascular endothelial cells: Role of plasminogen activator inhibitors
28. Introduction: Are natural anticoagulants candidates for modulating the inflammatory response to endotoxin?
29. Thrombin induces proteinase-activated receptor-1 gene expression in endothelial cells via activation of Gi-linked Ras/mitogen-activated protein kinase pathway
30. Hypotension and inflammatory cytokine gene expression triggered by factor Xa-nitric oxide signaling
31. Binding of human factor VIIa to tissue factor induces cytosolic Ca2+ signals in J82 cells, transfected COS-1 cells, Madin-Darby canine kidney cells and in human endothelial cells induced to synthesize tissue factor
32. Tissue factor signaling
33. How the protease thrombin talks to cells
34. Molecular cloning of a potential proteinase activated receptor
35. Mast cell tryptase stimulates human lung fibroblast proliferation via protease-activated receptor-2
36. Agonists of proteinase-activated receptor 2 induce inflammation by a neurogenic mechanism
37. Cleavage and activation of proteinase-activated receptor-2 on human neutrophils by gingipain-R from Porphyromonas gingivalis
38. Effector cell protease receptor-1 is a vascular receptor for coagulation factor Xa
39. Tissue factor and factor VIIa receptor/ligand interactions induce proinflammatory effects in macrophages
40. Endothelial protein C receptor
41. Identification of functional endothelial protein C receptor in human plasma
42. Structural and functional implications of the intron/exon organization of the human endothelial cell protein C/activated protein C receptor (EPCR) gene: Comparison with the structure of CD1/major histocompatibility complex alpha1 and alpha2 domains
43. Inflammotion, sepsis, and coagulation
44. Plasma levels of endothelial cell protein C receptor are elevated in patients with sepsis and systemic lupus erythematosus: Lack of correlation with thrombomodulin suggests involvement of different pathological processes
45. Proteinase-activated receptor-2-activating peptides induce leukocyte rolling, adhesion, and extravasation in vivo
46. Factor Xa as an interface between coagulation and inflammation: Molecular mimicry of factor Xa association with effector cell protease receptor-1 induces acute inflammation in vivo
47. In vivo immunosuppression by targeting a novel protease receptor
48. Fatal embryonic bleeding events in mice lacking tissue factor, the cell-associated initiator of blood coagulation
49. Targeted disruption of the murine tissue factor gene results in embryonic lethality
50. Sites of tissue factor pathway inhibitor (TFPI) and tissue factor expression under physiologic and pathologic conditions. On behalf of the Subcommittee on Tissue Factor Pathway Inhibitor (TFPI) of the Scientific and Standardization Committee of the ISTH
51. Regulation of the tissue factor promoter in endothelial cells: Binding of NF kappa B-, AP-1-, and Sp1-like transcription factors
52. Transcriptional regulation of the tissue factor gene in human epithelial cells is mediated by Sp1 and EGR-1
53. Vascular endothelial cell growth factor-induced tissue factor expression in endothelial cells is mediated by EGR-1
54. Bloodborne tissue factor: Another view of thrombosis
55. Significant correlations between tissue factor and thrombin markers in trauma and septic patients with disseminated intravascular coagulation
56. Effect of purified protein derivative and sonicates of Mycobacterium leprae and Mycobacterium bovis BCG on thromboplastin response in human monocytes in vitro
57. Induction of human endothelial tissue factor expression by Neisseria meningitidis: The influence of bacterial killing and adherence to the endothelium
58. Endotoxin liberation from Neisseria meningitidis correlates to their ability to induce procoagulant and fibrinolytic factors in human monocytes
59. Von Willebrand factor release and thrombomodulin and tissue factor expression in Rickettsia conorii-infected endothelial cells
60. Transcriptional regulation of endothelial cell tissue factor expression during Rickettsia rickettsii infection: Involvement of the transcription factor NF-kappaB
61. Rickettsia rickettsii infection of cultured human endothelial cells induces tissue factor expression
62. Bacterial species- and strain-dependent induction of tissue factor in human vascular endothelial cells
63. Stimulation of monocyte tissue factor expression in an in vitro model of bacterial endocarditis
64. Influence of monocytes and antibiotic treatment on tissue factor activity of endocardial vegetations in rabbits infected with Streptococcus sanguis
65. Serum-induced potentiation of tumor necrosis factor alpha production by human monocytes in response to staphylococcal peptidoglycan: Involvement of different serum factors
66. Similar cytokine induction profiles of a novel streptococcal exotoxin, MF, and pyrogenic exotoxins A and B
67. Production of tumor necrosis factors alpha and beta by human mononuclear leukocytes stimulated with mitogens, bacteria, and malarial parasites
68. Correlations and interactions in the production of interleukin-6 (IL-6), IL-1, and tumor necrosis factor (TNF) in human blood mononuclear cells: IL-6 suppresses IL-1 and TNF
69. In-vitro stimulation of TNF-alpha from human whole blood by cell-free supernatants of gram-positive bacteria
70. Effect of human recombinant cytokines on the induction of macrophage procoagulant activity
71. Contact activation proteins and the bacterial surface
72. Plasma kallikrein and Hageman factor in Gramnegative bacteremia
73. Activation of the intrinsic pathway of coagulation in children with meningococcal septic shock
74. Prognostic value of assessing contact system activation and factor V in systemic inflammatory response syndrome
75. Update on meningococcal disease with emphasis on pathogenesis and clinical management
76. Activation of the contact system in lethal hypotensive bacteremia in a baboon model
77. The contact system contributes to hypotension but not disseminated intravascular coagulation in lethal bacteremia: In vivo use of a monoclonal antifactor XII antibody to block contact activation in baboons
78. Pathogenesis of disseminated intravascular coagulation in sepsis
79. Assembly of human contact phase factors and release of bradykinin at the surface of curli-expressing Escherichia coli
80. Activation of the contact-phase system on bacterial surfaces: A clue to serious complications in infectious diseases
81. Role of kallikrein-kinin system in pathogenesis of bacterial cell wall-induced inflammation
82. Human kininogens interact with M protein, a bacterial surface protein and virulence determinant
83. Streptococcal M protein: Molecular design and biological behaviour
84. Absorption of kininogen from human plasma by Streptococcus pyogenes is followed by the release of bradykinin
85. Activation of rat mast cells by low molecular weight stimuli
86. Activation of clotting factor XI without detectable contact activation in experimental human endotoxemia
87. Activation of Hageman factor and prekallikrein and generation of kinin by various microbial proteinases
88. Bradykinin generation triggered by Pseudomonas proteases facilitates invasion of the systemic circulation by Pseudomonas aeruginosa
89. Effect of microbial and mite proteases on low and high molecular weight kininogens: Generation of kinin and inactivation of thiol protease inhibitory activity
90. Purification and characterization of a novel arginine-specific cysteine proteinase (argingipain) involved in the pathogenesis of periodontal disease from the culture supernatant of Porphyromonas gingivalis
91. Pathogenesis of periodontitis: A major arginine-specific cysteine proteinase from Porphyromonas gingivalis induces vascular permeability enhancement through activation of the kallikrein/kinin pathway
92. Purification and characterization of a potent 70-kDa thiol lysyl-proteinase (Lys-gingivain) from Porphyromonas gingivalis that cleaves kininogens and fibrinogen
93. Streptococcal cysteine proteinase releases kinins: A novel virulence mechanism
94. Current drug treatment strategies for disseminated intravascular coagulation
95. Disseminated intravascular coagulation: Pathophysiological mechanisms and manifestations
96. Regulation of leukocyte-endothelium interaction by fibrinogen
97. Role of fibrin deposition in the pathogenesis of intraabdominal infection
98. Evidence for three different fibrinogen-binding proteins with unique properties from Staphylococcus aureus strain Newman
99. Cloning and characterization of a gene for a 19 kDa fibrinogen-binding protein from Staphylococcus aureus
100. Molecular characterization of the clumping factor (fibrinogen receptor) of Staphylococcus aureus
101. Cloning, expression, and nucleotide sequence of a Staphylococcus aureus gene (fbpA) encoding a fibrinogen-binding protein
102. Surface protein adhesins of Staphylococcus aureus
103. Genetic evidence that bound coagulase of Staphylococcus aureus is not clumping factor
104. Lack of the extracellular 19-kilodalton fibrinogen-binding protein from Staphylococcus aureus decreases virulence in experimental wound infection
105. Role of Staphylococcus aureus coagulase and clumping factor in pathogenesis of experimental endocarditis
106. Clumping factor B (ClfB), a new surface-located fibrinogen-binding adhesin of Staphylococcus aureus
107. A fibrinogen-binding protein of Staphylococcus epidermidis
108. Functional studies of a fibrinogen binding protein from Staphylococcus epidermidis
109. Antibody responses in patients with staphylococcal septicemia against two Staphylococcus aureus fibrinogen binding proteins: Clumping factor and an extracellular fibrinogen binding protein
110. Fibrinogen binding and resistance to phagocytosis of Streptococcus sanguis expressing cloned M protein of Streptococcus pyogenes
111. Multiple binding of type 3 streptococcal M protein to human fibrinogen, albumin and fibronectin
112. Ultrastructural localization of the fibrinogen-binding domain of streptococcal M protein
113. Hyaluronate capsule and surface M protein in resistance to opsonization of group A streptococci
114. Molecular mechanisms of plasminogen activation: Bacterial cofactors provide clues
115. Effect of plasminogen activator (urokinase), plasmin, and thrombin on glycoprotein and collagenous components of basement membrane
116. Impaired wound healing in mice with a disrupted plasminogen gene
117. Physiological consequences of loss of plasminogen activator gene function in mice
118. Plasminogen: An important hemostatic parameter in septic patients
119. Recombinant tissue plasminogen activator restores perfusion in meningococcal purpura fulminans
120. Plasminogen activator inhibitor 1: A new prognostic marker in septic shock
121. Extreme plasminogen activator inhibitor and endotoxin values in patients with meningococcal disease
122. Plasminogen activation by invasive human pathogens
123. Use of the plasminogen activation system by microorganisms
124. Plasminogen activator activities of equimolar complexes of streptokinase with variant recombinant plasminogens
125. Activation of human plasminogen by staphylokinase: Direct evidence that preformed plasmin is necessary for activation to occur
126. Crystal structure of the catalytic domain of human plasmin complexed with streptokinase
127. The ternary microplasmin-staphylokinase-microplasmin complex is a proteinase-cofactor-substrate complex in action
128. Plasminogen activator/coagulase gene of Yersinia pestis is responsible for degradation of plasmid-encoded outer membrane proteins
129. Studies on the role of plasminogen activator in systemic infection by virulent Yersinia pestis strain C092
130. Binding of human plasminogen and urokinase-type plasminogen activator to the Lyme disease spirochete, Borrelia burgdorferi
131. Plasminogen, absorbed by Escherichia coli expressing curli or by Salmonella enteritidis expressing thin aggregative fimbriae, can be activated by simultaneously captured tissue-type plasminogen activator (t-PA)
132. The outer surface protein A of the spirochete Borrelia burgdorferi is a plasmin(ogen) receptor
133. Activation of interstitial collagenase, MMP-1, by Staphylococcus aureus cells having surfacebound plasmin: A novel role of plasminogen receptors of bacteria
134. Identification of a specific receptor for plasmin on a group A streptococcus
135. Plasminogen is required for efficient dissemination of B. burgdorferi in ticks and for enhancement of spirochetemia in mice
136. Selective distribution of a high-affinity plasminogen-binding site among group A streptococci associated with impetigo
137. New biological concepts on coagulation inhibitors
138. Plasma prekallikrein, factor XII, antithrombin III, C1(-)-inhibitor and alpha 2-macroglobulin in critically ill patients with suspected disseminated intravascular coagulation (DIC)
139. Septic shock, multiple organ failure, and disseminated intravascular coagulation: Compared patterns of antithrombin III, protein C, and protein S deficiencies
140. Derangements of coagulation and fibrinolysis in critically ill patients with sepsis and septic shock
141. Tissue factor pathway inhibitor: Potential therapeutic applications
142. The effect of twodomain tissue factor pathway inhibitor on endotoxin-induced disseminated intravascular coagulation in rabbits
143. Tissue factor pathway inhibitor reduces mortality from Escherichia coli septic shock
144. Recombinant E. coli-derived tissue factor pathway inhibitor reduces coagulopathic and lethal effects in the baboon gram-negative model of septic shock
145. Delayed treatment with recombinant human tissue factor pathway inhibitor improves survival in rabbits with gram-negative peritonitis
146. Randomized, blinded, placebo-controlled trial of tissue factor pathway inhibitor in porcine septic shock
147. Tissue factor pathway inhibitor blocks cellular effects of endotoxin by binding to endotoxin and interfering with transfer to CD14
148. Tissue factor pathway inhibitor dose-dependently inhibits coagulation activation without influencing the fibrinolytic and cytokine response during human endotoxemia
149. Coagulation inhibitor substitution during sepsis
150. Therapeutic applications of antithrombin concentrates in systemic inflammatory disorders
151. Recombinant human antithrombin III improves survival and attenuates inflammatory responses in baboons lethally challenged with Escherichia coli
152. Antithrombin III (ATIII) replacement therapy in patients with sepsis and/or postsurgical complications: A controlled double-blind, randomized, multicenter study
153. Effect of antithrombin III supplementation on inflammatory response in patients with severe sepsis
154. C1-inhibitor substitution therapy in septic shock and in the vascular leak syndrome induced by high doses of interleukin-2
155. Proteolytic inactivation of plasma C1-inhibitor in sepsis
156. Effect of C1 inhibitor on inflammatory and physiologic response patterns in primates suffering from lethal septic shock
157. Combined antithrombin III and C1-esterase inhibitor treatment decreases intravascular fibrin deposition and attenuates cardiorespiratory impairment in rabbits exposed to Escherichia coli endotoxin
158. C1 inhibitor in antiinflammatory therapy: From animal experiment to clinical application
159. C1-esterase inhibitor: An anti-inflammatory agent and its potential use in the treatment of diseases other than hereditary angioedema
160. Thrombomodulin-dependent anticoagulant activity is regulated by vascular endothelial growth factor
161. Recombinant thrombomodulin and activated protein C in the treatment of disseminated intravascular coagulation
162. Protein S and C4b-binding protein: Components involved in the regulation of the protein C anticoagulant system
163. Molecular analysis of the beta-chain of human C4b-binding protein
164. Endotoxin induced coagulation activation and protein C reduction in meningococcal septic shock
165. Coagulation activation and tissue necrosis in meningococcal septic shock: Severely reduced protein C levels predict a high mortality
166. Activated protein C concentrate for the treatment of meningococcal endotoxin shock in rabbits
167. Effects of a combined antithrombin III and protein C supplementation in porcine acute endotoxic shock
168. Infectious purpura fulminans: Diagnosis and treatment
169. The endothelial cell protein C receptor aids in host defense against Escherichia coli sepsis
170. A highly variable region in members of the streptococcal M protein family binds the human complement regulator C4BP
171. Bordetella pertussis binds the human complement regulator C4BP: Role of filamentous hemagglutinin
172. Molecular basis of host-pathogen interaction in septic shock
173. Gram-positive organisms and sepsis
174. Clinical gram-positive sepsis: Does it fundamentally differ from gram-negative bacterial sepsis?
175. Gram-positive sepsis: Mechanisms and differences from gram-negative sepsis
176. Dependence of vascular permeability enhancement on cysteine proteinases in vesicles of Porphyromonas gingivalis
177. Activation of bradykinin generating cascade by Vibrio cholerae protease
178. Activation of the plasma kallikrein-kinin system by Vibrio vulnificus protease
179. Identification of two laminin-binding fimbriae, the type 1 fimbria of Salmonella enterica serovar typhimurium and the G fimbria of Escherichia coli, as plasminogen receptors
180. Acquisition of plasmin activity by Fusobacterium nucleatum subsp. nucleatum and potential contribution to tissue destruction during periodontitis
181. Plasminogen binding and activation at the surface of Helicobacter pylori CCUG 17874
182. Mycoplasma cells stimulate in vitro activation of plasminogen by purified tissue-type plasminogen activator
183. Binding of plasminogen to Neisseria meningitidis and Neisseria gonorrhoeae and formation of surface-associated plasmin
184. Protease IV, a unique extracellular protease and virulence factor from Pseudomonas aeruginosa
185. Receptors for human plasminogen on gram-negative bacteria
186. Binding and activation of plasminogen at the surface of Staphylococcus aureus: Increase in affinity after conversion to the Lys form of the ligand
187. PAM, a novel plasminogenbinding protein from Streptococcus pyogenes
188. Streptokinase activates plasminogen bound to human group C and G streptococci through M-like proteins